Background: Besides the established guidelines, different region-specific recommendations for the use of DES exist worldwide, most are restricted to high-risk patients groups. Our aim was to evaluate the current PCI practice in a large population of patients in a real world clinical setting focusing on three main regions: Europe, Asia and Latin-America. Methods: e-NOBORI is a prospective, multinational, single-arm, multi-centre, observational registry. A total of 6087 patients have been enrolled in Europe, 887 in Asia and 776 in Latin-America. The primary endpoint of the study is target lesion failure (TLF) a composite of cardiac death (CD), target vessel myocardial infarction (MI) and target lesion revascularisation (TLR). Results: Patients: In Europe were oldest (63Ϯ12), with highest history of PCI (31%), and frequency of occluded and calcified lesions; In Asia were the youngest (57Ϯ11), more often diabetic (41%) with highest prevalence of multivessel disease (21%) and chronically occluded lesions (6%); and in Latin-America were more often female (25%), with the lowest number of lesions treated. Treatment of AMI was highest in Europe (30%) and lowest in Asia (9%), while distribution of left main (ϳ2%) and true bifurcation (ϳ5.5%) was similar. Pre-and post-dilatation were more often performed in Asia while Europe presented the highest rate of radial access (57%) and direct stenting (40%) with the lowest rate of post-dilatation (28%). At 1-month the rate of CD was 0,2%, 0,3% and 0,9%, MI 0,6%, 0,0% and 0,8% and TLR 0.8%, 0.0% and 0.0% for Europe, Asia and LatinAmerica, respectively. The TLF was 0,7%, 0,3% and 1.8%. Stent thrombosis frequency will be added at the time of the presentation along with fully adjudicated adverse events at 1-month and 1-year. Conclusions: Interesting findings were observed related to regional differences in procedure characteristics and complexity of the patients and lesions. Despite these differences the procedural success was over 99% for all three regions and the preliminary clinical outcomes showed similarly low TLF rate in this complex, all comer's population, treated with Nobori DES, in three continents.
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Impact of Ad Hoc Percutaneous Coronary Intervention with Drug-Eluting Stent in Angina Patients
Conclusions:
Ad hoc PCI using DES appears to be feasible for angina patients at a relatively low-risk of procedure. This approach may be reasonably performed with evaluation of objective ischemia using noninvasive or invasive tests. Background: Although direct stenting has become a daily practice and been proposed as an alternative for conventional stenting with predilatation, there have been no randomized evaluations using bare metal and drug eluting stents in elective PCI patients. The aim of this study was to assess clinical outcome of a strategy of direct stenting without pre-dilatation compared to conventional stenting with pre-dilatation or provisional stenting. Methods: A total of 1360 patients with stable or unstable angina pectoris or a recent (Ͻ30 days) myocardial infarction with objective evidence of myocardial ischemia were randomized to direct stenting, stenting after pre-dilatation or a provisional stenting strategy. The primary endpoint was the mean minimal lumen diameter (MLD) at follow-up angiography. The secondary endpoint was the clinical procedural success defined as angiographic success without major adverse cardiac events (MACE) at 9 months follow-up. Results: Follow-up angiography was performed in 367/736 pts in the BMS and in 524/532 pts in the DES cohort. Stents were used in 57.8% (BMS) and 77.5% (DES) of patients in the provisional arm. 
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